Sugammadex Piramal ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - neuromuskuläre blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Sugammadex Fresenius Kabi ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Mylan ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Adroiq ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed ইউরোপীয় ইউনিয়ন - জার্মান - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskuläre blockade - alle anderen therapeutischen produkte - umkehrung der neuromuskulären blockade durch rocuronium oder vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.